USA 99 , 1234512350 (2002)
Retatrutide is an investigational compound not yet approved by Health Canada or the FDA for weight management
T-47D cells were treated with IC 50 concentration of BV, DOX, and a mixture of bee venom and doxorubicin (BV + DOX) for 24 h each (0.99, 8.87, and 1.34 g/mL, respectively)
Read more on MIMS Pharma To view or add a comment, sign in Overview of GLP-1 Analogue Drugs: Brands, Companies & Clinical Uses GLP-1 analogues have transformed the treatment landscape for Type 2 Diabetes and obesity management offering better glycemic control, cardiovascular benefits, and effective weight loss
For these reasons, settlement projections are best understood as estimates based on prior dangerous drug litigation patterns, not a guarantee of compensation in any specific case